Immunovant bets on IMVT-1402
Autoimmune diseases specialist Immunovant (Nasdaq: IMVT) has opted to prioritize the development of IMVT-1402 as its lead asset due to its broad potential across a number of indications.
The New York-based company is set to begin four to five potentially registrational studies for the FcRn inhibitor in endocrinology, neurology, and other therapeutic areas in the next year. By the end of March 2026, Immunovant plans to start trials in a total of 10 indications.
"A combination of potentially best-in-class features not seen with any other FcRn inhibitor"Meanwhile, Immunovant is taking the foot off the gas in its development of batoclimab, another key asset. A top-line Phase III readout for the drug in myasthenia gravis had previously been expected in the second half of 2024, but this has now been pushed back to the end of March 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze